AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Therion Completes $36.5 Million Private Financing For Development.(Brief Article)
2001 NOV 21 - (NewsRx.com & NewsRx.net) -- Providing new resources to advance the company's clinical development programs, Therion Biologics has closed a $36.5 million private financing with leading venture investors.
Therion will use the funds to support clinical trials of PROSTVAC-VF, the company's lead cancer vaccine for prostate cancer, and to accelerate the development of its additional therapeutic cancer vaccine programs.
The financing was led by a group including Hans-Werner Hector, one of the founders of the German software company SAP. In addition to Hector's investment in Therion, he has established one of the largest private charitable foundations in Germany, through which he actively contributes to the fight against cancer and AIDS. Hector will also join the company's Board of Directors.
Other participants in the round included Sofinov, S.R. One Limited, H&Q Healthcare, H&Q Life Sciences, Loeb Investors, and several other prior Therion investors. Legg Mason Wood Walker, Inc., served as placement agent for the transaction.
"This year Therion has made strong clinical progress. Most significantly, we have demonstrated the ability of our proprietary cancer vaccines to enhance patient survival by eliciting a positive immune response against cancer,'' said Dennis Panicali, ...
- Therion Reports Results of Phase 2 PROSTVAC(R)-VF Trial at ASCO Annual Meeting...
- Press release article from: PR Newswire June 3, 2006 700+ words
...population." PROSTVAC-VF Phase 3 Study...with the National Cancer Institute (NCI) and Eastern...controlled Phase 3 PROSTVAC-VF trial, which...by the National Cancer Institute and is one of...in mid 2006. * PROSTVAC(R)-VF recently...cancer; a National Cancer ...
- Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial...
- Press release article from: PR Newswire July 7, 2005 700+ words
...the Phase II PROSTVAC-VF trial during...from National Cancer Institute (NCI) for conducting a Phase III PROSTVAC-VF trial with...Dana-Farber Cancer Institute. In addition...Phase II trial, PROSTVAC-VF is being...
- Therion Announces Oral Presentation of Data from Phase II PROSTVAC-VF Study in...
- Press release article from: PR Newswire May 16, 2005 700+ words
...targeted cancer therapy PROSTVAC(R)-VF program...conducted by the National Cancer Institute (NCI). The data...and treatment with PROSTVAC-VF was associated...data on Therion's PROSTVAC-VF program for prostate...Arlen of the National Cancer Institute (NCI) in an ASCO...
- BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM).
- Press release article from: PR Newswire February 25, 2009 700+ words
...In this National Cancer Institute (NCI) conducted study...based vaccine, or PROSTVAC(TM). The study...evaluated a combination of PROSTVAC(TM) vaccination...provided under an National Cancer Institute Clinical Trials Agreement...detailed results on PROSTVAC(TM) will be ...
- Bavarian Nordic reports further data on PROSTVAC(TM).
- News wire article from: Europe Intelligence Wire February 25, 2009 700+ words
...In this National Cancer Institute (NCI) conducted study...based vaccine, or PROSTVAC(TM). The study...evaluated a combination of PROSTVAC(TM) vaccination...provided under an National Cancer Institute Clinical Trials Agreement...detailed results on PROSTVAC(TM) will be ...
- PROSTVAC(TM) data accepted for an oral presentation at the ASCO Annual Meeting.
- News wire article from: Europe Intelligence Wire April 16, 2009 700+ words
...effects. In contrast, PROSTVAC(TM) has the potential...improved quality of life. PROSTVAC is being developed in...collaboration with the National Cancer Institute under a Cooperative...clinical trials to date PROSTVAC(TM) and related PSA...
- Therion Begins Phase II Clinical Trial of PROSTVAC-VF(R) as Immunotherapy for...
- Press release article from: PR Newswire November 19, 2003 700+ words
...priming" dose of PROSTVAC-VF in combination...at the Dana-Farber Cancer Institute. "Prostate cancer...pancreatic cancer and PROSTVAC-VF for prostate cancer...collaboration with the National Cancer Institute, the Company's strategic...
- New Review on PROSTVAC(TM) published by key Investigators from NCI.
- News wire article from: Europe Intelligence Wire July 1, 2009 700+ words
...effects. In contrast, PROSTVAC(TM) has the potential...improved quality of life. PROSTVAC is being developed in...collaboration with the National Cancer Institute under a Cooperative...clinical trials to date PROSTVAC(TM) and related PSA...
- New Review on PROSTVAC(TM) Published by Key Investigators From NCI.
- Press release article from: PR Newswire July 1, 2009 700+ words
...effects. In contrast, PROSTVAC(TM) has the potential...improved quality of life. PROSTVAC is being developed in...collaboration with the National Cancer Institute under a Cooperative...clinical trials to date PROSTVAC(TM) and related PSA...
- BN ImmunoTherapeutics reports further data on Prostvac.
- News wire article from: Chemical Business Newsbase February 25, 2009 700+ words
...cancer. In a National Cancer Institute (NCI) conducted study...based vaccine, or Prostvac. The study compared...The group receiving Prostvac had an improvement...evaluated a combination of Prostvac vaccination with an...provided under an National Cancer Institute Clinical ...
Source: HighBeam Research, Therion Completes $36.5 Million Private Financing For...